Literature DB >> 29263775

The Value of Pre-FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers.

Peter R Fendt1, Brian Ung1, F Randy Vogenberg2.   

Abstract

Year:  2017        PMID： 29263775      PMCID： PMC5726061     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

Review 1.  The FDA's regulation of health economic information.

Authors:  P J Neumann; K Claxton; M C Weinstein
Journal:  Health Aff (Millwood)       Date:  2000 Sep-Oct       Impact factor: 6.301

Review 2.  FDAMA Section 114: Why the Renewed Interest?

Authors:  Eleanor M Perfetto; Laurie Burke; Elisabeth M Oehrlein; Mena Gaballah
Journal:  J Manag Care Spec Pharm       Date:  2015-05

3.  AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.

Authors: 
Journal:  J Manag Care Spec Pharm       Date:  2016-12-22
  3 in total
  1 in total

1.  Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers: Opportunities Following the 21st Century Cures Act and FDA Guidance.

Authors:  Alexander Niyazov; Denise Lenci
Journal:  Front Public Health       Date:  2018-11-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.